Ivonescimab, the PD-1 and VEGF bispecific antibody that Summit Therapeutics licensed from China's Akeso, has been turned down by the US Food and Drug Administration for EGFR-mutated lung cancer after targeted therapy. Summit said on 15 November 2026 that the FDA issued a complete response letter because its HARMONi trial showed no statistically significant overall survival gain.
The decision means ivonescimab will not become the first PD-1 and VEGF bispecific antibody approved in the United States, at least for now. The medicine remains unapproved in Europe as well. In Ireland, it is being tested at three hospitals in a separate first-line lung cancer trial, HARMONi-3, which is not affected by the letter.
- Decision: the FDA issued a complete response letter for Summit's biologics licence application (BLA) for ivonescimab with platinum chemotherapy, announced by Summit on 15 November 2026. The FDA's target date was 14 November 2026.
- Indication sought: locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation, in patients previously treated with an EGFR tyrosine kinase inhibitor (TKI).
- Reason given: the FDA said substantial evidence of effectiveness was not established without a statistically significant improvement in overall survival.
- Trial result: HARMONi met its progression-free survival endpoint (hazard ratio 0.52), but the primary overall survival analysis (hazard ratio 0.79) did not reach statistical significance.
- Ireland and the EU: no European approval; HARMONi listed no Irish sites, while HARMONi-3 lists St James's Hospital and Beaumont Hospital in Dublin and Galway University Hospitals.
What did the FDA decide?
Summit's release says the complete response letter "indicates that the BLA cannot be approved in its present form". According to the company, the FDA determined that substantial evidence of effectiveness was not established in the absence of a statistically significant overall survival improvement. The agency also indicated that the progression-free survival benefit, without a statistically significant survival benefit, did not support a positive benefit-risk profile.
The application covered ivonescimab in combination with platinum-containing chemotherapy for people with EGFR-mutated, locally advanced or metastatic NSCLC whose disease had progressed after EGFR TKI treatment. Summit announced the BLA submission on 12 January 2026, and on 29 January it said the FDA had accepted the filing with a target action date of 14 November 2026.
Summit's release does not describe specific next steps with the FDA, such as a new trial or a resubmission. A complete response letter is the FDA's formal notice that an application cannot be approved as submitted and sets out what the agency found.
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit, said: "We are disappointed for patients and their families awaiting additional treatment options in this setting." Summit's release also notes that no FDA-approved regimen in this setting has shown a statistically significant overall survival benefit.
What is ivonescimab?
Ivonescimab is a bispecific antibody that blocks two targets at once: PD-1, an immune checkpoint used by tumours to avoid immune attack, and VEGF, a growth factor that helps tumours build blood vessels. It was invented by Akeso Inc., which is listed in Hong Kong, and is known as AK112 in Akeso's territories and SMT112 in Summit's.
Summit licensed the medicine in 2022 in a deal that pharmaphorum reports was worth up to 5 billion US dollars, including 500 million dollars upfront. Summit holds the rights in the United States, Europe and other territories, while Akeso keeps China. Summit's release says more than 5,000 patients have been treated with ivonescimab in clinical studies, and more than 100,000 when commercial use in China is included, according to Akeso. Our ivonescimab compound page lists current trials worldwide.
What did the HARMONi trial show?
HARMONi was a global, randomised, double-blind phase 3 trial comparing ivonescimab plus platinum chemotherapy with placebo plus chemotherapy in non-squamous NSCLC with an EGFR mutation, after a third-generation EGFR TKI. It had two primary endpoints, progression-free survival and overall survival. OncLive and Healio report that 438 patients were randomised, and Healio reports that 70% were Asian and 24% were white.
| Measure | Result |
|---|---|
| Median progression-free survival | 6.8 versus 4.4 months; hazard ratio 0.52 (95% CI 0.41 to 0.66), statistically significant |
| Median overall survival, primary analysis | 16.8 versus 14.0 months; hazard ratio 0.79 (95% CI 0.62 to 1.01), P = .0570, not statistically significant |
| Overall survival, Western patients over time | Hazard ratio 0.98 (April 2025), 0.84 (September 2025) and 0.76 (June 2026 final update), per Healio |
| Grade 3 or higher treatment-related side effects | 50.0% versus 42.2% (OncLive) |
| Stopped treatment due to side effects | 7.3% versus 5.0% (16 versus 11 patients) |
| Deaths from treatment-related side effects | 1.8% versus 2.3% (4 versus 5 patients) |
Summit argued that survival data were moving in the right direction with longer follow-up. Its release describes a post-hoc analysis showing a consistent hazard ratio of 0.76 in the full population, in Asian patients and in Western patients. Post-hoc analyses are carried out after the planned analysis, and the FDA's letter rests on the prespecified primary result. Summit describes the safety profile as acceptable and manageable, with no new safety signals.
Where is ivonescimab approved?
Only in China. Summit's release says ivonescimab was first approved for marketing in China in May 2024 and is not approved by any regulatory authority in Summit's licence territories, "including the United States and Europe". BioPharm International reports that China's National Medical Products Administration has approved three lung cancer uses: second-line EGFR-mutant NSCLC (HARMONi-A trial), first-line PD-L1-positive NSCLC (HARMONi-2), and, announced on 12 August 2026, first-line squamous NSCLC with chemotherapy (HARMONi-6).
Summit's release does not mention a European marketing authorisation application, and we found no public record of an application to the European Medicines Agency. Without an EU authorisation, the medicine cannot be marketed in Ireland.
Which other ivonescimab trials are under way?
Summit lists several ongoing studies in its territories. HARMONi-3 compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy as first-line treatment for metastatic NSCLC, analysing squamous and non-squamous cohorts separately. Pharmaphorum reports that squamous cohort data could arrive by the end of 2026 and non-squamous data in the first half of 2027. HARMONi-7 tests ivonescimab on its own as first-line treatment for metastatic NSCLC with high PD-L1 expression.
Other studies named by Summit cover colorectal cancer (HARMONi-GI3), urothelial cancer with enfortumab vedotin (HARMONi-GU1), kidney cancer, head and neck cancer (the GORTEC-sponsored ILLUMINE trial) and biliary tract cancer (ECOG-ACRIN). Summit also lists combination studies with partners including AstraZeneca and Daiichi Sankyo, Revolution Medicines, GSK and Arcus Biosciences. Pharmaphorum reports that AstraZeneca paid 2 billion dollars for a 10% stake in Summit in September 2026.
Are there ivonescimab trial sites in Ireland?
Yes, but not in the trial behind this decision. The ClinicalTrials.gov record for HARMONi (NCT06396065) lists sites in the United States, Canada, Spain, France, Italy and the United Kingdom, and none in Ireland.
The record for HARMONi-3 (NCT05899608) lists three Irish sites: St James's Hospital in Dublin, Beaumont Hospital in Dublin and Galway University Hospitals. The trial is listed as active, not recruiting, with a planned enrolment of 1,600 and sites in 17 countries. Patients taking part in any trial should speak to their study team about what, if anything, changes for them.
What does this mean for patients in Ireland?
For now, very little changes in practice, because ivonescimab was never available outside trials here. Any route to Irish patients would start with an EU marketing authorisation. After that, the HSE Corporate Pharmaceutical Unit would commission the National Centre for Pharmacoeconomics (NCPE) to assess the medicine, and the HSE would make the final reimbursement decision. None of these steps has started for ivonescimab as far as public records show.
People with lung cancer should discuss treatment options with their oncology team.
Frequently asked questions
Has the FDA rejected ivonescimab for all uses?
No. The complete response letter concerns one application, for EGFR-mutated NSCLC after EGFR TKI treatment. Other trials, including HARMONi-3 in first-line NSCLC, continue.
Why did the FDA turn it down?
According to Summit, the FDA said substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that the progression-free survival benefit alone did not support a positive benefit-risk profile.
Is ivonescimab approved in the EU or Ireland?
No. Summit says it is not approved by any regulator in its territories, including Europe.
Where is it approved?
In China, where Akeso markets it for three lung cancer uses.
Can patients in Ireland get it?
Only through a clinical trial. HARMONi-3 lists sites in Dublin and Galway but is listed as not recruiting.
Outlook
The next milestones are Summit's plans for the EGFR-mutated indication, which it has not yet set out, and the HARMONi-3 readouts expected from late 2026. For Ireland, the questions are whether Summit files in the EU and how HARMONi-3, with its three Irish sites, reads out. Priya Life Science will report on any European filing.
Sources
- Summit Therapeutics via Business Wire (republished by Finviz), Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application, 15 November 2026
- MarketScreener, Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval, 29 January 2026
- OncLive, FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC, 16 November 2026
- Healio, FDA rejects ivonescimab for EGFR-mutated locally advanced or metastatic NSCLC, 16 November 2026
- BioSpace, Summit's PD-1xVEGF rejected by FDA in lung cancer, 15 November 2026
- pharmaphorum, FDA won't approve Summit, Akeso's ivonescimab, 15 November 2026
- BioPharm International, NMPA Approves Ivonescimab Plus Chemotherapy for First-Line Squamous NSCLC Based on HARMONi-6 Data, 13 August 2026
- ClinicalTrials.gov, Phase III Study of AK112 for NSCLC Patients (HARMONi), NCT06396065, accessed 18 November 2026
- ClinicalTrials.gov, Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (HARMONi-3), NCT05899608, accessed 18 November 2026
- National Centre for Pharmacoeconomics, Submission process, accessed 18 November 2026
Cover image: AI-generated illustration.